Global testing kit shortages open new growth doors for Chinese companies

Date: 06 Apr 2020

Gene sequencing companies from China are stepping up nucleic acid kit exports as demand for quick, effective solutions to detect the novel coronavirus increases across the globe, experts said on Apr 1.

The confidence of the companies has been further boosted after several countries indicated that they would procure sufficient quantities of the high-quality test kits from China.

Data from, an industry monitoring platform under the National Association of Health Industry and Enterprise Management, showed that by March 28, detection equipment made by more than 110 Chinese in vitro diagnostic (IVD) enterprises have got the CE-IVD Marking and Free Sale Certificates. The certifications are necessary for IVD devices sold in Europe.

In the North American market, detection kits from BGI Genomics and Lupu Medical have received the Emergency Use Authorization issued by the United States Food and Drug Administration, indicating that their products can now be sold in the US clinical market.

With COVID-19 rapidly evolving into a pandemic, there is an acute shortage of detection equipment across the world, with the average daily demand hitting 500,000 to 700,000 kits, according to data from Huaxi Securities.

Wang Peijun, chairman of the committee for the radiology branch of the Shanghai Medical Association, said that although computerized tomography imaging offers valuable guidance on COVID-19 detection, nucleic acid detection is still the gold standard for case confirmations, as CT image shadows are present in other lung diseases.

Shenzhen, Guangdong province-based BGI, which also has the CE-IVD Marking, said following a spate of enquiries, it is now gearing up for exporting the detection kits. The company said international orders for BGI detection kits had surpassed 1 million by the end of March, covering 70 countries and regions. It has already made deliveries to Japan, Brunei, Thailand, Egypt, Peru, and the United Arab Emirates.

Chen Lili, a salesman with an East China-based detection kit manufacturer that he declined to identify, said overseas orders have been steadily increasing. The company has already removed regional restrictions for sales so that all its employees can handle overseas orders.

Shi Xiaochen, an ultrasound physician at Peking University People's Hospital, said the global shortage of detection kits was due to the epidemic outbreak, as the growth in patients was way in excess of the emergency treatment capabilities of local hospitals.

Yin Ye, CEO of BGI Genomics, said: "China's growing capabilities in medical devices, especially IVD research and manufacturing in the last 10 years, have created a strong platform to deal with the boom in sudden demand."

Zhang Yan, an expert with Willingmed, a Beijing-based medical technology developer, said: "The fight against the epidemic has spurred the 'go-global' process of Chinese IVD manufacturers. Domestic firms have already made considerable progress in the research and development of detection kits since the epidemic appeared in China. Overseas companies are learning from these experiences and more willing to import our products."

Starting Wednesday, exporters of medical products, including COVID-19 testing kits, medical face masks and ventilators, need to provide extra documentation when they go through Customs clearance, according to the commerce ministry.

China's epidemic experiences have proved that the products are qualified and trustworthy, Zhang said.

IVDs have become an important subcategory of the medical equipment sector and have huge growth potential. Markets-and-Markets, an industry research consultancy, expects the global IVD market to attain a value of $75.1 billion this year. Multinational corporations, including Abbott, Roche, Siemens, Danaher, and Thermo Fisher, account for over 50 percent of the market share.

However, domestic IVD firms are also catching up. According to the report from Beijing-based research firm China Stone, in 2018, China's IVD sector grew at a rate of 18.43 percent year-on-year, way higher than the global rate, which was less than 5 percent.

With the country's enhanced medical insurance system and advanced technologies, the sector is expected to witness compound annual growth rates of over 15 percent in the next five to 10 years, the report said.

Source: China Daily

相关搜索 万孚梅毒检测试纸 试剂盒图片 疫情什么意思 作者最新文章 突发!美国百年银行破产,英国再提群体免疫,全球日增确诊首超10万 瑞幸COO只是“背锅侠”不持股权?最高时身价曾达1.2亿美元 华盛顿州宣布疫情趋缓 让出400多台呼吸机给纽约 相关文章 梁文道:疫情危机下的经济形势与就业 炒作中国口罩质量不合格?三起事件全部反转!某些人疫情期间还想打压中国制造,意欲何为? 谢晓亮:如何从康复者血浆的海量抗体中快速找到新冠“杀器” 中国免疫学会理事长:病例锐减,新冠疫苗临床试验或移海外 美国累计确诊超30万!世卫组织:疫情不仅仅是健康危机 设为首页© Baidu 使用百度前必读 意见反馈 京ICP证030173号  京公网安备1
The information on this page may have been provided by a contributor to ChinaGoAbroad, and ChinaGoAbroad makes no guarantees about the accuracy of any content. All content shall be used for informational purposes only. Contributors must obtain all necessary licenses and/or ownership rights from the relevant content owner(s) before submitting such content (including texts, pictures, photos and diagrams) to ChinaGoAbroad for publication. ChinaGoAbroad disclaims all liability arising from the publication of any content/information (such as texts, pictures, photos and diagrams that infringe on any copyright) received from contributors. Links may direct to third party sites out of the control of ChinaGoAbroad, and such links shall not be considered an endorsement by ChinaGoAbroad of any information contained on such third party sites. Please refer to our Disclaimer for more details.